Stealth Peptides Inc. Announces FDA IND Approval for Conduct of Clinical Studies with Bendavia(TM), A Mitochondrial Targeted Therapy for Ischemia Reperfusion Injury

ROCKVILLE, Md.--(BUSINESS WIRE)--Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative therapies, announced today that the U.S. Food and Drug Administration (FDA) approved its Investigational New Drug (IND) application for Bendavia™. Bendavia is a new chemical entity that targets mitochondria to treat ischemia reperfusion injury, which commonly occurs with many cardiovascular, renal and neurologic insults. Stealth’s lead clinical program is for acute myocardial infarction (AMI), an indication with clear clinical metrics for FDA marketing approvals and demonstrating the beneficial biologic activity of Bendavia.